Organon & Co. (OGN): Price and Financial Metrics
GET POWR RATINGS... FREE!
OGN POWR Grades
- OGN scores best on the Value dimension, with a Value rank ahead of 99.48% of US stocks.
- OGN's strongest trending metric is Stability; it's been moving down over the last 177 days.
- OGN ranks lowest in Momentum; there it ranks in the 7th percentile.
OGN Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for OGN is -6.92 -- better than only 2.43% of US stocks.
- With a one year PEG ratio of 618.14, ORGANON & CO is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 95.32% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -9.81 for ORGANON & CO; that's greater than it is for just 2.01% of US stocks.
- Stocks that are quantitatively similar to OGN, based on their financial statements, market capitalization, and price volatility, are CMPR, AZYO, DESP, DCFC, and PRTK.
- To dig deeper into the stock's financial statements, go to OGN's page on browse-edgar?action=getcompany&CIK=0001821825.
OGN Valuation Summary
- In comparison to the median Healthcare stock, OGN's price/sales ratio is 80.85% lower, now standing at 0.9.
- Over the past 23 months, OGN's EV/EBIT ratio has gone up 5.8.
Below are key valuation metrics over time for OGN.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| OGN | 2023-03-24 | 0.9 | -6.2 | 6.1 | 8.9 |
| OGN | 2023-03-23 | 0.9 | -6.1 | 5.9 | 8.8 |
| OGN | 2023-03-22 | 0.9 | -6.2 | 6.1 | 8.9 |
| OGN | 2023-03-21 | 0.9 | -6.4 | 6.2 | 9.0 |
| OGN | 2023-03-20 | 0.9 | -6.4 | 6.2 | 9.0 |
| OGN | 2023-03-17 | 0.9 | -6.2 | 6.0 | 8.9 |
OGN Price Target
For more insight on analysts targets of OGN, see our OGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $41.80 | Average Broker Recommendation | 1.62 (Moderate Buy) |
OGN Stock Price Chart Interactive Chart >
OGN Price/Volume Stats
| Current price | $22.68 | 52-week high | $39.09 |
| Prev. close | $22.24 | 52-week low | $20.96 |
| Day low | $22.25 | Volume | 1,712,000 |
| Day high | $22.73 | Avg. volume | 2,197,602 |
| 50-day MA | $26.35 | Dividend yield | 5.07% |
| 200-day MA | $28.02 | Market Cap | 5.77B |
Organon & Co. (OGN) Company Bio
Organon & Co. Organon & Co. is a science-based global pharmaceutical company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. Its women's health portfolio includes Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. Its operating segments include the Organon Products segment. The Organon Products segment is engaged in developing and delivering health solutions through its portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's products segment portfolio includes: Women's Health, Biosimilars and Established Brands. Women's Health contains contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing and elonva. The Company's Biosimilars portfolio consists of three immunology products: Brenzys, Renflexis and Hadlima; and two oncology products: Ontruzant and Aybintio.
Latest OGN News From Around the Web
Below are the latest news stories about ORGANON & CO that investors may wish to consider to help them evaluate OGN as an investment opportunity.
Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities ExistJERSEY CITY, N.J., March 07, 2023--Organon Launches "Her Plan is Her Power," a New Global Initiative to Reduce Unplanned Pregnancies Where Need is Great and Disparities Exist |
Organon Canada receives the Women in Governance (WiG) Parity Certification SME, further demonstrating its commitment to gender parity in the workplaceOrganon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is excited to share that in line with National Employee Appreciation Day on March 3, it has received the Women in Governance Parity Certification SME 1. The WiG Parity Certification SME is a national benchmark recognizing notable organizations for their ongoing efforts and commitments to gender parity in the workplace. Through integrating numerous programs and policies across the organization, Organon Canada ha |
Ahead of International Women's Day, Organon Canada Spotlights the Importance of Supporting Women's Equity While Highlighting the Cost of Not Investing in Their HealthFor far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon Canada, a subsidiary of Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers and others – to consider the consequences of the growing health disparities that women are currently facing. In Canada, for the second consecutive year, the company |
Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2022JERSEY CITY, N.J., February 16, 2023--Organon (NYSE: OGN) today announced its results for the fourth quarter and full year ended December 31, 2022. |
Ahead of International Women's Day, Organon Calls for Recognition of the Impacts of Underinvesting in Women's HealthFor far too long, women's health issues have been underfunded, under researched and underserved. Leading up to International Women's Day on March 8, Organon (NYSE: OGN), a global women's health company, is challenging the healthcare ecosystem – along with academia, investors, policymakers, researchers, and others – to consider the consequences of continuing to treat women's health as an afterthought. For the second consecutive year, the company is also providing its employees, including over 400 |
OGN Price Returns
| 1-mo | -7.39% |
| 3-mo | -17.93% |
| 6-mo | -0.88% |
| 1-year | -34.12% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -17.93% |
| 2022 | -4.86% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
OGN Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Loading social stream, please wait...